NCT07607912Not yet recruiting
Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus
Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus: A Monocentric Ambispective Observational Study
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time. The study will include adults with diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS. Researchers will study whether glycemic control worsens after surgery and whether this risk changes according to the type of pancreatic resection. The study will also examine changes in glucose metabolism, and cancer-related outcomes. Information from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 408 (estimated)
- First submitted
- 21 May 2026
- Start date
- May 2026
- Primary completion date
- May 2037
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Pancreatic cancer, Type 2 diabetes
- NCT number
- NCT07607912
What you commit to
- Study type: Observational
- Planned participants: 408
- From May 2026 to the primary completion date, May 2037
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Absence of diabetes mellitus at baseline
- Severe pre-existing non-oncologic clinical conditions with life expectancy \<6 months
Age
- Age \<18 years
Other
- Missing essential clinical data or incomplete follow-up precluding evaluation of study outcomes
- Refusal, withdrawal, or inability to provide informed consent for the ambispective and prospective components, where applicable
Who the study is looking for
- Adult patients (≥18 years)
- Diabetes mellitus at baseline
- Undergoing partial, near-total, or total pancreatectomy at the study center for benign or malignant pancreatic disease
- Availability of clinical and metabolic follow-up data according to study component
- Written informed consent for the ambispective and prospective components, where applicable
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.